Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (DE:0K4)
FRANKFURT:0K4
Holding DE:0K4?
Track your performance easily
0K4 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€16.50 - €32.78
Previous CloseN/A
Volume0.00
Average Volume (3M)23.00
Market Cap
$1.71B
Enterprise Value€1.31B
Total Cash (Recent Filing)$598.00K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Mar 13, 2025EPS Estimate
-1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding69,799,150
10 Day Avg. Volume28
30 Day Avg. Volume23
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.71
Forecast
1Y Price Target
€50.35Price Target Upside116.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Akero Therapeutics News
PremiumCompany Announcements
Akero Therapeutics Advances in MASH Treatment Trials
PremiumPre-Earnings
Is AKRO a Buy, Before Earnings?Options Prices
Currently, No data available
---
Ownership Overview
3.51% Insiders
26.83% Mutual Funds
<0.01% Other Institutional Investors
56.62% Public Companies and Individual Investors
0K4 FAQ
What was Akero Therapeutics Inc’s price range in the past 12 months?
Akero Therapeutics Inc lowest stock price was €16.50 and its highest was €32.78 in the past 12 months.
What is Akero Therapeutics Inc’s market cap?
Akero Therapeutics Inc’s market cap is $1.71B.
When is Akero Therapeutics Inc’s upcoming earnings report date?
Akero Therapeutics Inc’s upcoming earnings report date is Mar 13, 2025 which is in 50 days.
How were Akero Therapeutics Inc’s earnings last quarter?
Akero Therapeutics Inc released its earnings results on Nov 08, 2024. The company reported -€1.019 earnings per share for the quarter, missing the consensus estimate of -€0.853 by -€0.166.
Is Akero Therapeutics Inc overvalued?
According to Wall Street analysts Akero Therapeutics Inc’s price is currently Undervalued.
Does Akero Therapeutics Inc pay dividends?
Akero Therapeutics Inc does not currently pay dividends.
What is Akero Therapeutics Inc’s EPS estimate?
Akero Therapeutics Inc’s EPS estimate is -1.13.
How many shares outstanding does Akero Therapeutics Inc have?
Akero Therapeutics Inc has 69,799,150 shares outstanding.
What happened to Akero Therapeutics Inc’s price movement after its last earnings report?
Akero Therapeutics Inc reported an EPS of -€1.019 in its last earnings report, missing expectations of -€0.853. Following the earnings report the stock price went down -1.83%.
Which hedge fund is a major shareholder of Akero Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:0K4
---
Akero Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€50.35 (116.17% Upside)
€50.35 (116.17% Upside)
Blogger Sentiment
Bullish
DE:0K4 Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $520.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.32%
12-Months-Change
Fundamentals
Return on Equity
-35.90%
Trailing 12-Months
Asset Growth
28.68%
Trailing 12-Months
Company Description
Akero Therapeutics Inc
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
---
0K4 Stock 12 Month Forecast
Average Price Target
€50.35
▲(116.17% Upside)
Technical Analysis
Akero Therapeutics
―
89bio
―
Prime Medicine, Inc.
―
Terns Pharmaceuticals
―
Viking Therapeutics
―
Altimmune
―
ESSA Pharma
―
Best Analysts Covering 0K4
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-1.27%
reiterated a buy rating 11 months ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -1.27% per trade.
---